April 24, 2011

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

.   .   

This large randomized multicentre trial showed delayed onset of microalbuminuria in Type 2 diabetics with normoalbuminuria that were treated with olmesartan 40 mg daily as compared to the placebo group, but a higher rate of fatal cardiovascular events in those with preexisting heart disease.

Editorial http://www.nejm.org/doi/full/10.1056/NEJMe1014147
UKidney Discussion http://qx.md/y

Related Articles:

General Nephrology

Comments are closed.